Ablation for Paroxysmal Atrial Fibrillation

Mechanism and Procedural Technique

The European Society of Cardiology recommends catheter ablation for symptomatic patients with paroxysmal atrial fibrillation who have failed at least one attempt at antiarrhythmic drug therapy (Class IIa, Level A) 1, 3
The procedure creates circumferential lesions around the pulmonary vein ostia to electrically isolate these triggers from the rest of the left atrium 1
The American Heart Association suggests that catheter ablation can be considered as initial therapy (Class IIb) in selected patients with symptomatic paroxysmal atrial fibrillation, without significant cardiac disease, who remain highly symptomatic despite rate control and refuse antiarrhythmic drug therapy 1, 3

The European Society of Cardiology recommends catheter ablation for patients with paroxysmal atrial fibrillation who have failed at least one attempt at antiarrhythmic drug therapy (Class IIa, Level A) 1, 3
The European Society of Cardiology suggests that ablation can be considered as initial therapy (Class IIb) in patients with paroxysmal atrial fibrillation without significant cardiac disease 1, 3

Catheter ablation achieves approximately 90% success rate in paroxysmal atrial fibrillation, although multiple procedures are often necessary to achieve these results 5
The success rate at one year varies from 73-80% freedom from atrial fibrillation after pulmonary vein isolation, but 29-41% of patients require a second procedure 5

Major complications occur in approximately 6% of procedures 5
The risk of stroke/thromboembolism is 0-5%, preventable with appropriate periprocedural anticoagulation 5
Atrio-esophageal fistula is a rare but often fatal complication that requires high vigilance 5

The European Society of Cardiology recommends that low molecular weight heparin or unfractionated heparin should be considered as "bridge therapy" before resuming oral anticoagulation, which should be continued for at least 3 months (Class IIa, Level C) 1
Long-term anticoagulation therapy is recommended in patients with 1 major risk factor or >2 clinically relevant non-major risk factors (i.e., CHA₂DS₂-VASc score >2), regardless of apparent success of ablation 1, 5

All patients should undergo 12-lead ECG and/or Holter monitoring to document the nature of the arrhythmia, and transthoracic echocardiogram to identify/exclude underlying cardiac disease before the procedure 1
The operator's experience is a fundamental consideration when considering ablation as a therapeutic option, as the studies cited in support of the recommendations were almost exclusively performed by highly experienced operators in specialized institutions 3, 4